ArticleCancer discovery2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
Registry-linked trialAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04015622 (A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone), which is not on this map. Cited by 162 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 1 pooled it
14.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04015622 phase2active not recruitingnot on this mapstarted 2020, after this paper: background citation
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone
Who cites it
162 citing papers in PubMed, 1 synthesis or guideline pooled it, 260 citations in OpenAlex.
- PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.JCO precision oncology · 2021Pooled it
- Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.Proceedings of the National Academy of Sciences of the United States of America · 2026Trial
- Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.Nature medicine · 2025Trial
- Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer.Molecular cancer therapeutics · 2026Article
- Mechanisms and disease relevance of DNA break repair pathway choice.Nature reviews. Molecular cell biology · 2026Review
- Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.International urology and nephrology · 2026Review
- Review
- Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.Cancers · 2026Review
- Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance.Experimental hematology & oncology · 2026Review
- Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Nature · 2026Article
- Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review.Frontiers in oncology · 2026Review
- Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.Cancer medicine · 2026Article
- SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes.Cancer biology & therapy · 2025Article
- Exploring drug resistance via intercellular crosstalk using spatial transcriptomics in high-grade serous ovarian carcinoma.NPJ precision oncology · 2025Article
- A Case of Metastatic Castration-Resistant Prostate Cancer WithIJU case reports · 2025Article
- Therapeutic resistance and combination therapy for cancer: recent developments and future directions.Scientific reports · 2025Article
- Clinical approaches to overcome PARP inhibitor resistance.Molecular cancer · 2025Review
- Genome-wide CRISPR activation screen identifies ARL11 as a sensitivity determinant of PARP inhibitor therapy.Cancer gene therapy · 2025Article
- Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review.BJC reports · 2025Article
- HIF-1α-induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP-ribosylation.Clinical and translational medicine · 2025Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 8 institutions in 4 countries.
David QuigleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Alexander W WyattVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.
Vishal KothariHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Adam FoyeHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Paul LloydHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Won KimHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Eric LuKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Jacob SchwartzmanKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Kevin BejaVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.
Matti AnnalaVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, British Columbia, Canada.
Rajdeep DasHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Morgan DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Colin PritchardDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.
George ThomasKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Scott TomlinsDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan.
Karen KnudsenDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Christopher J LordThe CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
Charles RyanHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Jack YoungrenHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California. Felix.Feng@ucsf.edu Eric.Small@ucsf.edu Alan.Ashworth@ucsf.edu.
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California. Felix.Feng@ucsf.edu Eric.Small@ucsf.edu Alan.Ashworth@ucsf.edu.
Felix Y FengHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California. Felix.Feng@ucsf.edu Eric.Small@ucsf.edu Alan.Ashworth@ucsf.edu.
University of California, San Francisco · USOregon Health & Science University · USUniversity of British Columbia · CABreast Cancer Now · GBSidney Kimmel Cancer Center · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Michigan · USUniversity of Washington · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7MUSP22 Function in Advanced Prostate CancerR01CA182569 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E, MCMAHON, STEVEN B. · 2015 to 2019
$2.4MCancer Research UK 14276Cancer Research UK 24439NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA182569
Abstract
Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as
Indexed as
Antineoplastic AgentsBRCA2 ProteinCell-Free Nucleic AcidsDNA Copy Number VariationsDrug Resistance, NeoplasmExome SequencingGerm-Line MutationHumansMalePhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsProstatic NeoplasmsAntineoplastic AgentsBRCA2 ProteinBRCA2 protein, humanCell-Free Nucleic AcidsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitorstalazoparib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04015622ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.